Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases

Table 9 Risk of atypical hemolytic uremic syndrome recurrence according to the implicated genetic abnormalities

Gene mutation	Location	Functional Impact	Mutation frequency in aHUS (%)	Recurrence after transplantation (%)
CFH	Plasma	Loss	20-30	75-90
CFI	Plasma	Loss	2-12	45-80
CFB	Plasma	Gain	1-2	100
C3	Plasma	Gain	5-10	40-70
MCP	Membrane	Loss	10-15	15-20
THBD	Membrane	Loss	5	One case
Homozygous CFHR1 del (3%-8%)	Circulating	Undetermined	14-23 (> 90% with anti-CHF AB)	NA

Adapted from Salvadori et al[1]. aHUS: Atypical hemolytic uremic syndrome; NA: Not available; CFH: Complement factor H; CFI: Complement factor I; CFB: Complement factor B; C3: Complement 3; MCP: Membrane cofactor protein; THBD: Thrombomodulin.